Cyclooxygenase-2/carbonic anhydrase-IX up-regulation promotes invasive potential and hypoxia survival in colorectal cancer cells

Journal of Cellular and Molecular Medicine

Volumn 13, Issue 9 B, 2009, Pages 3876-3887

  Sansone, Pasquale ^a,b   Piazzi, Giulia ^a,b   Paterini, Paola ^a,b   Strillacci, Antonio ^b   Ceccarelli, Claudio ^b   Minni, Francesco ^b   Biasco, Guido ^a   Chieco, Pasquale ^a   Bonafè, Massimiliano ^a,b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CA IX; Colon cancer; COX 2; Hypoxia; Inflammation

Indexed keywords

EID: 77449140110     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00580.x     Document Type: Article

References (49)

1. Edge SB, Sobin LH, Page DL. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2005, 97:463-4. author reply 464-5
2. Taniguchi K, Kakinuma S, Tokairin Y. Mild inflammation accelerates colon carcinogenesis in Mlh1-deficient mice. Oncology. 2007, 71:124-30.
3. Zhang J, Stirling B, Temmerman ST. Impaired regulation of NF-kappaB and increased susceptibility to colitis-associated tumorigenesis in CYLD-deficient mice. J Clin Invest. 2006, 116:3042-9.
4. Yang L, Pei Z. Bacteria, inflammation, and colon cancer. World J Gastroenterol. 2006, 14:6741-6.
5. Steinbach G, Lynch PM, Phillips RK. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000, 342:1946-52.
6. Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005, 23:2840-55.
7. Eberhart CE, Coffey RJ, Radhika A. Up-regulation of cyclooxygenase-2 gene-expression in human colorectal adenomas and adenocarcinomas. Gastroenterology. 1994, 107:1183-8.
8. Backlund MG, Mann JR, Dubois RN. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology. 2005, 69:S28-32.
9. Tsujii M, Kawano S, Tsuji S. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998, 93:705-16.
10. Sinicrope FA, Gill S. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev. 2004, 23:63-75.
11. Oshima M, Dinchuk JE, Kargman SL. Suppression of intestinal polyposis in Apc (D716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 1996, 87:803-9.
12. Kaidi A, Qualtrough D, Williams AC. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res. 2006, 66:6683-91.
13. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer. 2002, 2:38-47.
14. Tatum JL, Kelloff GJ, Gillies RJ. Hypoxia: importance in tumor biology, non invasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006, 82:699-757.
15. Graeber TG, Osmanian C, Jacks T. Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996, 379:88-91.
16. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007, 26:225-39.
17. Swinson DE, Jones JL, Richardson D. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol. 2003, 21:473-82.
18. Hussain SA, Ganesan R, Reynolds G. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer. 2007, 96:104-9.
19. Brennan DJ, Jirstrom K, Kronblad A. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res. 2006, 12:6421-31.
20. Goethals L, Debucquoy A, Perneel C. Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys. 2006, 65:246-54.
21. Kopacek J, Barathova M, Dequiedt F. MAPK pathway contributes to density- and hypoxia-induced expression of the tumor-associated carbonic anhydrase IX. Biochim Biophys Acta. 2005, 1729:41-9.
22. Kaluz S, Kaluzová M, Stanbridge EJ. The role of extracellular signal-regulated protein kinase in transcriptional regulation of the hypoxia marker carbonic anhydrase IX. J Cell Biochem. 2006, 97:207-16.
23. Sansone P, Storci G, Giovannini C. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells. 2007, 25:807-15.
24. Krysan K, Reckamp KL, Dalwadi H. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res. 2005, 65:6275-81.
25. Strillacci A, Griffoni C, Spisni E. RNA interference as a key to knockdown overexpressed cyclooxygenase-2 gene in tumour cells. Br J Cancer. 2006, 94:1300-10.
26. Hamilton SR, Aaltonen LA. Tumors of the colon and rectum. Pathology and genetics of tumours of the digestive system WHO classification of tumours 2000, 103. In, Lyon, IARC Press, p
27. Chrastina A, Zavada J, Parkkila S. Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int J Cancer. 2003, 105:873-8.
28. Zat'ovicova M, Tarabkova K, Svastova E. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-associated hypoxia-induced carbonic anhydrase IX. J Immunol Methods. 2003, 282:117-34.
29. Detre S, Saclani Jotti G, Dowsett M. A " quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995, 48:876-8.
30. Wykoff CC, Beasley NJ, Watson PH. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000, 60:7075-83.
31. Sheng H, Shao J, Washington MK. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001, 276:18075-81.
32. Saxena NK, Sharma D, Ding X. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res. 2007, 67:2497-507.
33. Byun JH, Lee MA, Roh SY. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer. Jpn J Clin Oncol. 2006, 36:263-8.
34. Lee KW, Kim MS, Kang NJ. H-Ras selectively up-regulates MMP-9 and COX-2 through activation of ERK1/2 and NF-kappaB: an implication for invasive, phenotype in rat liver epithelial cells. Int J Cancer. 2006, 119:1767-75.
35. Svastova E, Hulikova A, Rafajova M. Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett. 2004, 577:439-45.
36. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev. 2007, 26:299-310.
37. Uenoyama Y, Seno H, Fukuda A. Hypoxia induced by benign intestinal epithelial cells is associated with cyclooxygenase-2 expression in stromal cells through AP-1-dependent pathway. Oncogene. 2006, 25:3277-85.
38. Jakubickova L, Biesova Z, Pastorekova S. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines. Int J Oncol. 2005, 26:1121-7.
39. Hilska M, Roberts PJ, Collan YU. Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer. 2007, 121:714-23.
40. Saarnio J, Parkkila S, Parkkila AK. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol. 1998, 153:279-85.
41. Soumaoro LT, Uetake H, Higuchi T. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res. 2004, 10:8465-71.
42. Cleven AH, van Engeland M, Wouters BG. Stromal expression of hypoxia regulated proteins is an adverse prognostic factor in colorectal carcinomas. Cell Oncol. 2007, 29:229-40.
43. Oosterling SJ, van der Bij GJ, Meijer GA. Macrophages direct tumour histology and clinical outcome in a colon cancer model. J Pathol. 2005, 207:147-55.
44. Petersen VC, Baxter KJ, Love SB. Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer. Gut. 2002, 51:65-9.
45. Liao Z, Mason KA, Milas L. Cyclo-oxygenase-2 and its inhibition in cancer: is there a role. Drugs. 2007, 67:821-45.
46. Winum JY, Thiry A, Cheikh KE. Carbonic anhydrase inhibitors. Inhibition of isoforms I, II, IV, VA, VII, IX, and XIV with sulfonamides incorporating fructopyranose-thioureido tails. Bioorg Med Chem Lett. 2007, 17:2685-91.
47. Dogne JM, Thiry A, Pratico D. Dual carbonic anhydrase-cyclooxygenase-2 inhibitors. Curr Top Med Chem. 2007, 7:885-91.
48. Stubbs M, McSheehy PM, Griffiths JR. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000, 6:15-9.
49. Winum JY, Rami M, Scozzafava A. Carbonic anhydrase IX: a new druggable target for the design of antitumor agents. Med Res Rev. 2008, 28:445-63.